Loading...
XWARCRM
Market cap7mUSD
Dec 23, Last price  
0.36PLN
1D
-6.08%
1Q
-30.12%
Jan 2017
-82.93%
IPO
-91.23%
Name

PZ Cormay SA

Chart & Performance

D1W1MN
XWAR:CRM chart
P/E
—
P/S
0.36
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
1.44%
Rev. gr., 5y
3.33%
Revenues
82m
-3.67%
31,085,00038,451,00061,940,00090,027,000105,473,000100,800,000100,111,00045,004,00082,277,00077,585,00069,793,00068,410,00065,290,00084,732,00085,361,00082,225,000
Net income
-4m
L-32.33%
1,420,0002,956,0006,130,00014,008,00015,382,0006,853,000-47,357,000-5,157,000-10,990,000-2,021,000-24,982,000-40,974,000-12,821,0001,635,000-6,644,000-4,496,000
CFO
-3m
L-62.69%
2,203,000-1,582,000-9,747,0002,334,0002,254,000-17,451,0007,928,000-5,271,000-5,167,0001,656,000-1,561,000-4,390,000-161,000-1,469,000-8,709,000-3,249,000

Profile

PZ Cormay S.A. develops, manufactures, and sells diagnostic reagents in Poland. It offers testing products for clinical chemistry, hematology, veterinary, urinalysis, and parasitology, as well as rapid test products. The company serves small and medium size clinical laboratories, clinics, and hospitals. It distributes its products to approximately 120 countries. PZ Cormay S.A. was founded in 1985 and is headquartered in Lomianki, Poland.
URL
https://cormay.com/
IPO date
Aug 20, 2008
Employees
222
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
82,225
-3.67%
85,361
0.74%
84,732
29.78%
Cost of revenue
87,426
88,853
87,647
Unusual Expense (Income)
NOPBT
(5,201)
(3,492)
(2,915)
NOPBT Margin
Operating Taxes
681
402
79
Tax Rate
NOPAT
(5,882)
(3,894)
(2,994)
Net income
(4,496)
-32.33%
(6,644)
-506.36%
1,635
-112.75%
Dividends
(5)
(279)
Dividend yield
0.01%
0.29%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,279
1,212
1,273
Long-term debt
8,549
6,624
6,062
Deferred revenue
636
794
Other long-term liabilities
953
192
250
Net debt
(244)
(7,163)
(23,332)
Cash flow
Cash from operating activities
(3,249)
(8,709)
(1,469)
CAPEX
(5,634)
(8,435)
(6,746)
Cash from investing activities
5,520
8,969
(4,724)
Cash from financing activities
(19)
(1,337)
(619)
FCF
2,599
10,333
(36,631)
Balance
Cash
10,020
14,947
30,618
Long term investments
52
52
49
Excess cash
5,961
10,731
26,430
Stockholders' equity
(43,471)
(31,055)
(27,108)
Invested Capital
105,006
96,359
95,620
ROIC
ROCE
EV
Common stock shares outstanding
84,205
84,205
84,205
Price
0.59
-33.71%
0.89
-22.87%
1.15
0.00%
Market cap
49,513
-33.71%
74,690
-22.87%
96,836
0.00%
EV
49,681
68,023
74,355
EBITDA
(1,758)
1,114
1,424
EV/EBITDA
61.06
52.22
Interest
1,064
936
467
Interest/NOPBT